glp-1 agonist weight loss Part 2 of a 3-Part Series; Medications for The GLP-1 Agonists and Obesity:
Description
Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis
served on scientific advisory panels and/or speakers bureaus and served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk and Sanofi
Schrempft S, Jimnez-Snchez C, Baysson H, Zaballa ME, Lamour J, Stringhini S, et al
The exact dose varies from person to person and should always be determined by a healthcare provider
